VERAXA Biotech AG (NASDAQ: VRXA) announced on July 20 that it has received positive Scientific Advice from Germany's Paul-Ehrlich-Institute (PEI) regarding its lead BiTAC(R)-TCE program. The regulatory feedback supports the company's proposed development strategy, including its biological rationale, safety assessments, and non-clinical development plan for the novel therapeutic platform. This milestone is expected to reduce development uncertainty by providing greater clarity before the company advances to clinical studies.
The BiTAC(R)-TCE platform is designed to generate bispecific T-cell engagers that redirect the body's immune system to target and eliminate cancer cells. VERAXA's lead candidate previously demonstrated encouraging preclinical data, which was presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The company believes the PEI's guidance aligns with its efforts to bring next-generation antibody therapeutics to patients.
Scientific Advice procedures allow drug developers to consult with regulatory experts before initiating clinical trials, helping to ensure that development plans meet expectations for safety, efficacy, and manufacturing. By engaging with the PEI early, VERAXA aims to streamline its path to first-in-human studies. The company continues to build a diversified oncology pipeline that includes not only BiTAC(R)-TCE candidates but also antibody-drug conjugates (ADCs) and other engineered antibody formats (https://ibn.fm/zBiDU).
Veraxa's latest regulatory achievement follows continued progress in manufacturing and development. The company is focused on advancing its proprietary platform to address unmet medical needs in oncology. As an emerging leader in designing novel cancer therapies, VERAXA leverages its BiTAC(R)-TCE technology to create potent and selective immune engagers.
The positive feedback from the PEI represents a critical step forward for the company, potentially accelerating the timeline for clinical development. Investors can access the latest news and updates regarding VRXA in the company’s newsroom at https://ibn.fm/VRXA.
